Replies to post #9186 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Equal, I like your thinking. My figures were not grounded in any concrete data. Also, I was justing projecting potential milestones, not factoring in the % royalties on sales which is in addition to milestone payments. I agree since we are near the finish line on AXAL/cervical cancer the % royalties on sales/revenue sharing would be much higher than the typical 10% royalties on sales you see in deals that start from pre-clinical.

[ignatiusrielly35]

What is the status of AXAL P3 anyway. Have they begun enrolling yet?